Table of Contents
ITP – an update
Idiopathic Thrombocytopenic Purpura
Acute (post-viral) ITP vs Chronic ITP
Clinical Course of ITP
PPT Slide
Antigen never eradicated
The Diagnosis of ITP
BCSH guidelines – Adult (Chronic) ITP
Adult ITP – Laboratory Investigations
Does Acute Lymphoblastic Leukemia Present with Isolated Thrombocytopenia?
Adult ITP – Antiplatelet Antibodies
Adult ITP – Helicobacter pylori
ITP Therapies and Natural History
Overall ITP-related mortality
Mortality Rates – Severe, refractory adult ITP
Relative risk of adult ITP-related mortality in refractory patients
Morbidity and Mortality in ITP
Why is Serious Bleeding So Uncommon in ITP?
Thrombocytopenia and the Bleeding Risk
Outcome & Hemorrhagic Risks
Recommendation for ‘Safe’ Platelet Counts in Adults
Potential Treatment Considerations in ITP
Initial Treatment Decisions
‘Non-Treatment of ITP is a Misnomer’
Adults: First-Line Therapy
More lasting response to first line therapy ? High dose Dexamethasone
PPT Slide
Intravenous anti-D immunoglobulin Comparison of 50µg/kg vs. 75µg/kg
IV anti-D Therapy:Use in Maintenance
Long Term Follow Up Median 26 (range 6 to 54) mos
Adults: Second-Line Therapy
Hazards of Splenectomy
Treatment of Chronic Refractory ITP
Treatment of Chronic Refractory ITP
Failed Splenectomy: Simple Measures
Rituximab Therapy for ITP
Rituximab Is an Alternative to Splenectomy in Adults With Chronic ITP: Results of a Multicenter Prospective Phase II Study
Efficacy and Safety of Rituximab in the Treatment of Refractory/Relapsed ITP: Results of a Meta-Analysis in 299 Patients
Duration of Response to Rituximab in Patients with Chronic ITP with Response Duration > 1 year
Limitations of anti CD 20 ab treatment
Future Treatment Prospects
Thrombopoietin Involved at All Stages
Thrombopoietin-Like Drugs
2nd Generation Thrombopoietic Growth Factors
PPT Slide
AMG 531 - Long-Term Open-Label Extension Study Mean Platelet Counts and Mean Dose (N=34)
Treatment Aims in ITP
|